This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Naluzotan
Accession Number
DB05562
Type
Small Molecule
Groups
Investigational
Description
Not Available
Structure
Thumb
Synonyms
Not Available
External IDs
PRX-00023
Categories
UNII
LQ54E5B4EW
CAS number
740873-06-7
Weight
Average: 450.64
Monoisotopic: 450.266462274
Chemical Formula
C23H38N4O3S
InChI Key
SPWZXWDPAWDKQE-UHFFFAOYSA-N
InChI
InChI=1S/C23H38N4O3S/c1-20(28)25-22-10-7-11-23(18-22)27-16-14-26(15-17-27)13-6-5-12-24-31(29,30)19-21-8-3-2-4-9-21/h7,10-11,18,21,24H,2-6,8-9,12-17,19H2,1H3,(H,25,28)
IUPAC Name
N-(3-{4-[4-(cyclohexylmethanesulfonamido)butyl]piperazin-1-yl}phenyl)acetamide
SMILES
CC(=O)NC1=CC=CC(=C1)N1CCN(CCCCNS(=O)(=O)CC2CCCCC2)CC1

Pharmacology

Indication

Investigated for use/treatment in anxiety disorders and depression.

Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
U5-hydroxytryptamine receptor 1A
agonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe metabolism of Naluzotan can be decreased when combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AmikacinThe risk or severity of adverse effects can be increased when Amikacin is combined with Naluzotan.Approved, Investigational, Vet Approved
AmphetamineThe metabolism of Naluzotan can be decreased when combined with Amphetamine.Approved, Illicit, Investigational
BenmoxinThe metabolism of Naluzotan can be decreased when combined with Benmoxin.Withdrawn
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Naluzotan.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Naluzotan.Approved
BrofaromineThe metabolism of Naluzotan can be decreased when combined with Brofaromine.Experimental
BromocriptineBromocriptine may increase the vasoconstricting activities of Naluzotan.Approved, Investigational
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Naluzotan.Approved
CabergolineCabergoline may increase the vasoconstricting activities of Naluzotan.Approved
CaroxazoneThe metabolism of Naluzotan can be decreased when combined with Caroxazone.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Naluzotan.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Naluzotan.Approved, Investigational
ClindamycinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Naluzotan.Approved, Vet Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Naluzotan.Approved, Illicit
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Naluzotan.Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Naluzotan.Approved
DihydroergotamineDihydroergotamine may increase the vasoconstricting activities of Naluzotan.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Naluzotan.Approved
DotarizineThe risk or severity of adverse effects can be increased when Naluzotan is combined with Dotarizine.Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Naluzotan.Approved, Vet Approved
DroxidopaNaluzotan may increase the hypertensive activities of Droxidopa.Approved, Investigational
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Naluzotan.Approved, Investigational
Ergoloid mesylateErgoloid mesylate may increase the vasoconstricting activities of Naluzotan.Approved
ErgonovineErgonovine may increase the vasoconstricting activities of Naluzotan.Approved
ErgotamineErgotamine may increase the vasoconstricting activities of Naluzotan.Approved
EthanolNaluzotan may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Naluzotan.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Naluzotan.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Naluzotan.Approved, Illicit, Investigational, Vet Approved
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Naluzotan.Approved
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Naluzotan.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Naluzotan.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Naluzotan is combined with Fluvoxamine.Approved, Investigational
FurazolidoneThe metabolism of Naluzotan can be decreased when combined with Furazolidone.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Naluzotan.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Naluzotan.Approved, Investigational
HarmalineThe metabolism of Naluzotan can be decreased when combined with Harmaline.Experimental
HydracarbazineThe metabolism of Naluzotan can be decreased when combined with Hydracarbazine.Experimental
HydrocodoneNaluzotan may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Naluzotan.Approved
IproclozideThe metabolism of Naluzotan can be decreased when combined with Iproclozide.Withdrawn
IproniazidThe metabolism of Naluzotan can be decreased when combined with Iproniazid.Withdrawn
IsocarboxazidThe metabolism of Naluzotan can be decreased when combined with Isocarboxazid.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Naluzotan.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Naluzotan.Approved, Investigational
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Naluzotan.Approved, Investigational
Magnesium carbonateThe risk or severity of adverse effects can be increased when Magnesium carbonate is combined with Naluzotan.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Magnesium citrate is combined with Naluzotan.Approved
Magnesium sulfateThe therapeutic efficacy of Naluzotan can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Naluzotan.Approved
MebanazineThe metabolism of Naluzotan can be decreased when combined with Mebanazine.Withdrawn
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Naluzotan.Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Naluzotan.Approved
Methylene blueThe metabolism of Naluzotan can be decreased when combined with Methylene blue.Approved, Investigational
MethylergometrineMethylergometrine may increase the vasoconstricting activities of Naluzotan.Approved
MinaprineThe metabolism of Naluzotan can be decreased when combined with Minaprine.Approved
MoclobemideThe metabolism of Naluzotan can be decreased when combined with Moclobemide.Approved, Investigational
NialamideThe metabolism of Naluzotan can be decreased when combined with Nialamide.Withdrawn
OctamoxinThe metabolism of Naluzotan can be decreased when combined with Octamoxin.Withdrawn
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Naluzotan.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Naluzotan.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Naluzotan.Approved, Investigational, Vet Approved
PargylineThe metabolism of Naluzotan can be decreased when combined with Pargyline.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Paromomycin is combined with Naluzotan.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Naluzotan is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Naluzotan.Experimental
PhenelzineThe metabolism of Naluzotan can be decreased when combined with Phenelzine.Approved
PheniprazineThe metabolism of Naluzotan can be decreased when combined with Pheniprazine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Naluzotan.Approved, Investigational
PhenoxypropazineThe metabolism of Naluzotan can be decreased when combined with Phenoxypropazine.Withdrawn
PirlindoleThe metabolism of Naluzotan can be decreased when combined with Pirlindole.Approved
PivhydrazineThe metabolism of Naluzotan can be decreased when combined with Pivhydrazine.Withdrawn
PramipexoleNaluzotan may increase the sedative activities of Pramipexole.Approved, Investigational
PregabalinThe therapeutic efficacy of Naluzotan can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
ProcaineThe metabolism of Naluzotan can be decreased when combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe metabolism of Naluzotan can be decreased when combined with Procarbazine.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Naluzotan.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Naluzotan.Approved, Investigational
PseudoephedrineThe risk or severity of adverse effects can be increased when Naluzotan is combined with Pseudoephedrine.Approved
PyrantelThe risk or severity of adverse effects can be increased when Pyrantel is combined with Naluzotan.Approved, Vet Approved
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Naluzotan.Approved
RasagilineThe metabolism of Naluzotan can be decreased when combined with Rasagiline.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Naluzotan.Approved
SafrazineThe metabolism of Naluzotan can be decreased when combined with Safrazine.Withdrawn
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Naluzotan.Approved, Investigational
SelegilineThe metabolism of Naluzotan can be decreased when combined with Selegiline.Approved, Investigational, Vet Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Naluzotan.Approved, Investigational
TetracyclineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Naluzotan.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Naluzotan.Investigational
ToloxatoneThe metabolism of Naluzotan can be decreased when combined with Toloxatone.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Naluzotan.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Naluzotan.Approved, Investigational
TranylcypromineThe metabolism of Naluzotan can be decreased when combined with Tranylcypromine.Approved, Investigational
TrimethadioneThe risk or severity of adverse effects can be increased when Trimethadione is combined with Naluzotan.Approved
VancomycinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Naluzotan.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Naluzotan.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Vinpocetine is combined with Naluzotan.Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Naluzotan.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Naluzotan.Approved, Investigational
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Naluzotan.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
9605731
BindingDB
50187377
ChEMBL
CHEMBL209821
Wikipedia
Naluzotan

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentMajor Depressive Disorder (MDD)1
2TerminatedTreatmentEpilepsies / Epilepsy, Localization Related / Temporal Lobe Epilepsy1
3CompletedTreatmentAnxiety Disorders1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0489 mg/mLALOGPS
logP2.68ALOGPS
logP2.53ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)11.08ChemAxon
pKa (Strongest Basic)7.64ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area81.75 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity127.77 m3·mol-1ChemAxon
Polarizability51.92 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Rickels K, Mathew S, Banov MD, Zimbroff DL, Oshana S, Parsons EC Jr, Donahue SR, Kauffman M, Iyer GR, Reinhard JF Jr: Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2008 Apr;28(2):235-9. doi: 10.1097/JCP.0b013e31816774de. [PubMed:18344738]
  2. de Paulis T: Drug evaluation: PRX-00023, a selective 5-HT1A receptor agonist for depression. Curr Opin Investig Drugs. 2007 Jan;8(1):78-86. [PubMed:17263189]
  3. Iyer GR, Reinhard JF Jr, Oshana S, Kauffman M, Donahue S: Tolerability, pharmacokinetics, and neuroendocrine effects of PRX-00023, a novel 5-HT1A agonist, in healthy subjects. J Clin Pharmacol. 2007 Jul;47(7):817-24. doi: 10.1177/0091270007300953. Epub 2007 May 10. [PubMed:17495280]

Drug created on November 18, 2007 11:26 / Updated on August 02, 2018 05:31